# Combination of TATE and PD-1 Inhibitor in Liver Cancer

> **NCT03259867** · PHASE2 · RECRUITING · sponsor: **Teclison Ltd.** · enrollment: 54 (estimated)

## Conditions studied

- Hepatocellular Carcinoma
- Gastric Cancer

## Interventions

- **DRUG:** Nivolumab Injectable Product
- **COMBINATION_PRODUCT:** Trans-arterial tirapazamine embolization

## Key facts

- **NCT ID:** NCT03259867
- **Lead sponsor:** Teclison Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2017-07-01
- **Primary completion:** 2026-12-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03259867

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03259867, "Combination of TATE and PD-1 Inhibitor in Liver Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03259867. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*